Baiyun Mountain Dongtai Shangqiu Pharmaceutical Co. Ltd.

Main study objectives: To investigate the pharmacokinetic characteristics of the test preparation Allopurinol Tablets and the reference preparation Allopurinol Tablets in healthy adult Chinese subjects after a single oral administration (fasting/postprandial), and to evaluate the bioequivalence of the two preparations after oral administration under fasting and postprandial conditions. Secondary study objectives: To evaluate the safety of a single oral administration of one tablet of the test preparation and the reference preparation in healthy adult Chinese subjects under fasting/postprandial conditions.

Main study objectives To evaluate the pharmacokinetic characteristics and bioequivalence of the test formulation of tadalafil tablets (specification: 20 mg, applicant: Baiyun Shandong Tai Shangqiu Pharmaceutical Co., Ltd.) and the reference formulation (Cialis®, specification: 20 mg, licensee: Eli Lilly Nederland B.V.) after a single oral dose under fasting and postprandial conditions in healthy Chinese adult male subjects. Secondary study objectives To study the safety of the test formulation of tadalafil tablets (specification: 20 mg) and the reference formulation (trade name: Cialis®, specification: 20 mg) in healthy Chinese adult male subjects.

Main study objectives: To investigate the pharmacokinetic characteristics of the test preparation Allopurinol Tablets and the reference preparation Allopurinol Tablets in healthy adult Chinese subjects after a single oral administration (fasting/postprandial), and to evaluate the bioequivalence of the two preparations after oral administration under fasting and postprandial conditions. Secondary study objectives: To evaluate the safety of the test preparation and the reference preparation at a single oral administration of 0.1g (fasting/postprandial) in healthy adult Chinese subjects.